摘要
目的比较利拉鲁肽和格列美脲治疗2型糖尿病的效果及其安全性。方法选择2014年1月至2015年2月周口市中心医院接诊的80例2型糖尿病患者为研究对象,按随机数字表法分为对照组和观察组,各40例。观察组皮下注射利拉鲁肽,每日1次,初始剂量为0.6 mg/d,治疗1周后增加至1.2 mg/d;对照组口服格列美脲,每日1次,初始剂量为1 mg/d,每周根据血糖的变化对用药进行调整。两组患者均治疗3个月。比较两组患者在治疗后的体质指数、糖化性血红蛋白、餐后2 h血糖以及空腹血糖、用药的安全性以及临床疗效。结果治疗后3个月,观察组糖化血红蛋白、餐后2 h血糖以及空腹血糖低于对照组[(6.5±0.8)%比(8.1±0.9)%,(9.3±0.6)mmol/L比(12.5±0.9)mmol/L,(6.3±1.1)mmol/L比(9.4±1.7)mmol/L],差异有统计学意义(P<0.01)。观察组收缩压降低的发生率高于对照组[27.5%(11/40)比7.5%(3/40)],体质指数增加和低血糖的发生率低于对照组[2.5%(1/40)比22.5%(9/40),7.5%(3/40)比25.0%(10/40)],差异有统计学意义(P<0.05)。观察组临床疗效优于对照组,差异有统计学意义(P<0.05)。结论利拉鲁肽治疗2型糖尿病的效果明显优于格列美脲,其降低了低血糖的发生率,且能降低体质量,增加安全性,值得在临床上推广。
Objective To compare the therapeutic effect and safety of liraglutide and glimepiride for type 2 diabetes. Methods Total of 80 type 2 diabetes patients admitted to Henan Zhoukou Central Hospital from Jan. 2014 to Feb. 2015 were randomly divided into a control group and an observation group,40 cases each. The observation group was treated with liraglutide subcutaneously, once daily, initially at a dose of 0. 6 mg/d, increased to 1.2 mg/d one week later. The control group was treated with glimepiride, once daily, with the initial dose of 1 mg/d, then adjusted according to blood glucose changes weekly. Both groups were treated for three months. The BMI, glycated hemoglobin, fasting blood glucose and postprandial 2 h blood glucose, medication safety and clinical efficacy of the two groups after treatment were compared. Results After 3 months of treatment, glycated hemoglobin, 2 h postprandial blood glucose and fasting blood glucose of the observation group were lower than the control group [ （ 6. 5 ± 0.8 ） % vs （ 8. 1 ± 0. 9 ） %, （9.3±0.6） mmol/L vs （12.5±0.9） mmol/L, 6.3±1. 1） mmol/L vs （9.4±1.7） mmol/L] ,the differences were statistically significant（ P 〈 0.01 ）. Systolic blood pressure of the observation group was higher than the control group [ 27.5 % （ 11/40 ） vs 7.5 % （3/40） ], body mass index increase and the proportion of hypoglycemia of the observation group were lower than the control group[ 2.5% （1/40） vs 22.5% （9/40）, 7.5% （ 3/40 ） vs 25.0% （ 10/40 ） ], the differences were statistically significant （ P 〈 0. 05 ）. Clinical efficacy of the observation group was higher than the control group ,the difference was statistically significant （P 〈 0. 05 ）. Conclusion Liraglutide is better than glimepiride for the treatment of type 2 diabetes, which reduces the incidence of hypoglycemia and body mass loss ,and increase the safety ,thus is worthy of the promotion in clinical.
出处
《医学综述》
2016年第13期2696-2698,共3页
Medical Recapitulate
